# Sangamo Therapeutics, Inc (SGMOQ)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/sangamo-therapeutics-inc/ JSON: https://steadybase.io/company/sangamo-therapeutics-inc.json Checked Nov 10, 2026. Latest filing read: May 14, 2026.

## Company

- Legal name: SANGAMO THERAPEUTICS, INC
- Ticker: SGMOQ (OTC)
- SEC CIK: 0001001233
- Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
- Headquarters: Richmond, CA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: sangamo.com
- LinkedIn: https://www.linkedin.com/company/sangamo-therapeutics
- Next earnings date: Dec 20, 2026 (estimated from past 8-K timing)

## Key facts

- Revenue: $39.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/0001628280-26-022029-index.html
- Operating income: -$121.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/0001628280-26-022029-index.html
- Net income: -$122.9M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/0001628280-26-022029-index.html
- SG&A: $34.9M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/0001628280-26-022029-index.html
- Employees: 142 as of Mar 27, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/sgmo-20251231.htm
- Shares outstanding: 414,288,847 as of May 11, 2026 (10-Q filed May 14, 2026). Source: https://www.sec.gov/Archives/edgar/data/1001233/000162828026035067/0001628280-26-035067-index.html
- Auditor: Ernst & Young LLP, San Mateo, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/sgmo-20251231.htm

## Business

We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. We believe our zinc finger epigenetic regulators are ideally suited to potentially address devastating neurology disorders and our capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system, or CNS, in preclinical studies.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/sgmo-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $39.6M | -$121.2M | -$122.9M | $34.9M |
| Dec 31, 2024 | $57.8M | -$104.0M | -$97.9M | $44.7M |
| Dec 31, 2023 | $176.2M | -$274.0M | -$257.8M | $61.2M |
| Dec 31, 2022 | $111.3M | -$201.3M | -$192.3M | $62.7M |
| Dec 31, 2021 | $110.7M | -$183.3M | -$178.3M | $63.2M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/sangamo-therapeutics-inc.json

## Officers and directors

- Sandy Macrae, PRESIDENT, CEO AND DIRECTOR. Source: Form 4 filed May 27, 2026, https://www.sec.gov/Archives/edgar/data/1001233/000167568726000008/0001675687-26-000008-index.htm
- Nathalie Dubois-Stringfellow, SVP-CHIEF DEVELOPMENT OFFICER. LinkedIn: https://linkedin.com/in/duboisstringfellow. Source: Form 4 filed May 27, 2026, https://www.sec.gov/Archives/edgar/data/1001233/000194700726000012/0001947007-26-000012-index.htm
- Nikunj Jain, Principal Accounting Officer. Source: Form 4 filed May 27, 2026, https://www.sec.gov/Archives/edgar/data/1001233/000208921326000008/0002089213-26-000008-index.htm
- Scott B. Willoughby, SVP, CHIEF LEGAL OFFICER, SECY. LinkedIn: https://linkedin.com/in/scottwilloughby. Source: Form 4 filed May 27, 2026, https://www.sec.gov/Archives/edgar/data/1001233/000187736826000008/0001877368-26-000008-index.htm
- Prathyusha Duraibabu, PRINCIPAL FINANCIAL OFFICER. Source: Form 4 filed Jan 26, 2026, https://www.sec.gov/Archives/edgar/data/1001233/000177909226000002/0001779092-26-000002-index.htm
- Gregory D. Davis, Head of Research & Technology. Source: Form 4 filed May 27, 2026, https://www.sec.gov/Archives/edgar/data/1001233/000204185526000010/0002041855-26-000010-index.htm

## Recent 8-K events

- Oct 27, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1001233/000119312526434171/d179328d8k.htm
- Oct 16, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1001233/000119312526423054/d453907d8k.htm
- Sep 21, 2026: Item 1.03, Bankruptcy or receivership; Item 2.01, Completion of acquisition or disposition of assets; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1001233/000119312526396644/d178611d8k.htm
- Sep 8, 2026: Item 1.03, Bankruptcy or receivership; Item 2.01, Completion of acquisition or disposition of assets; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1001233/000110465926105905/tm2624942d1_8k.htm
- Aug 28, 2026: Item 1.01, Entry into a material definitive agreement; Item 1.03, Bankruptcy or receivership; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1001233/000119312526374328/d116527d8k.htm
- Aug 13, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1001233/000119312526347524/d125617d8k.htm
- Aug 12, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1001233/000119312526346796/d21956d8k.htm
- Jul 20, 2026: Item 1.03, Bankruptcy or receivership; Item 3.01, Notice of delisting or failure to meet listing standards. Source: https://www.sec.gov/Archives/edgar/data/1001233/000119312526309012/d125683d8k.htm
- Jul 1, 2026: Item 4.01, Changes in registrant's certifying accountant; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1001233/000119312526292501/d113173d8k.htm
- Jun 23, 2026: Item 1.01, Entry into a material definitive agreement; Item 1.03, Bankruptcy or receivership; Item 2.03, Creation of a direct financial obligation; Item 2.05, Costs associated with exit or disposal activities (restructuring). Source: https://www.sec.gov/Archives/edgar/data/1001233/000119312526278582/d161847d8k.htm

## Insider trades (Form 4)

- Apr 22, 2026: Gregory D. Davis (Head of Research & Technology) sold 69,827 shares, about $17,457. Source: https://www.sec.gov/Archives/edgar/data/1001233/000204185526000008/0002041855-26-000008-index.htm
- Apr 21, 2026: Nathalie Dubois-Stringfellow (SVP-CHIEF DEVELOPMENT OFFICER) sold 345,942 shares, about $89,945. Source: https://www.sec.gov/Archives/edgar/data/1001233/000194700726000010/0001947007-26-000010-index.htm

## What management said

- "During the first quarter, we advanced our rolling BLA submission for ST-920 and continued to progress our differentiated neurology pipeline" Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics (8-K filed May 14, 2026). Source: https://www.sec.gov/Archives/edgar/data/1001233/000162828026035061/exhibit-991051426.htm

## Latest filings

- 8-K filed Oct 27, 2026: https://www.sec.gov/Archives/edgar/data/1001233/000119312526434171/d179328d8k.htm
- 10-K filed Mar 30, 2026: https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/sgmo-20251231.htm
- 10-Q filed May 14, 2026: https://www.sec.gov/Archives/edgar/data/1001233/000162828026035067/sgmo-20260331.htm
- DEF 14A filed Apr 30, 2025: https://www.sec.gov/Archives/edgar/data/1001233/000162828025020773/sgmo-20250429.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/